A Letter From Our CEO

To Our Clients, Vendors and Investors,

Medpace understands the tremendous impact on communities and individuals worldwide as a result of COVID-19.  As communities around the world manage their responses to this pandemic, we remain committed to our mission of accelerating the global development of safe and effective medical therapeutics.

Medpace has implemented essential steps to protect the health and welfare of our employees and their families, our study participants and vendors, while at the same time ensuring we continue to serve our sponsors and our mission.

Business Continuity

We have implemented an Incident Management Team comprised of our most senior management which meets daily to assess the most recent developments and take any necessary steps to ensure ongoing operations are maintained while ensuring the safety of our associates.

Our technology infrastructure has the capacity to support an expanded remote work environment. We are implementing virtual meetings with our employees, sponsors and investigators.  We are working directly with all our sponsors to ensure the preservation of patient safety, and data by assessing the impacts presented by localized quarantines, potential supply interruptions and healthcare facility re-prioritization.

We are putting forth every resource to ensure our managed clinical trials continue to be advanced, that our efforts do not put clinical site staff and patients at undue risk and our studies remain in compliance with governmental policies.

We have instituted virtual monitoring in high-impact/restricted regions, and we are equipped to commence remote monitoring across the globe as circumstances dictate. Our study teams have been and will continue to directly connect with their counterparts at our sponsors and managed sites to facilitate workable plans.

Personal Safety

The health and safety of our employees and their families, our customers, patients and our communities are a priority. Medpace already had a significant population of employees who work remote, and that has continued.  For our office-based population, we have transitioned to either a fully remote working environment or a staggered work schedule to alleviate the stress on transportation systems, to promote social distancing and provide our employees with a safer work environment.   Since the initial outbreak of COVID-19, we have had in place ongoing deep cleaning of our offices and common areas.  In all jurisdictions, we are following the requirements and recommendations of local health authorities.

Non-essential Travel

As travel restrictions continue to change and expand, we are following all imposed restrictions while continuing necessary study related travel. We have restricted corporate travel to all materially impacted locations and are monitoring all employees’ personal travel.  We have eliminated non-essential interoffice travel.

We will continue to evaluate our responses as circumstances evolve, always with our intention to keep our associates safe and serve our clients and study participants.

Thank you,

August J. Troendle, M.D.
Chief Executive Officer